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ABSTRACT
Background:Limited therapies are available for large (≥40 mm) unresectable 
hepatocellular carcinoma (HCC). Currently, the standard treatment with transarterial 
chemoembolisation (TACE) is unsatisfactory with high recurrence rate and limited 
effect on survival. Laser Ablation (LA) has emerged as a relatively new technique 
characterized by high efficacy and good safety. This study is aimed to evaluate the 
efficacy of LA in comparison to TACE in patients with large HCC.
Methods: Eighty-two patients with a single HCC nodule ≥40 mm (BCLC stage A or 
B) were enrolled in this case-control study. Forty-one patients were treated with LA 
and 41 patients were treated with TACE. Response to therapy was evaluated according 
to the mRECIST criteria. Survival was calculated with Kaplan-Meier from the time of 
cancer diagnosis to death with values censored at the date of the last follow-up.
Results: Twenty-six (63.4%) and 8 (19.5%) patients had a complete response 
after LA and TACE, respectively (p < 0.001). Subsequently we stratified the HCCs in 
3 categories according to the nodule size: 40–50 mm, 51–60 mm, and >60 mm. LA 
resulted superior to TACE especially in nodules ranging between 51 and 60 mm in 
diameter, with a complete response rate post-LA and post-TACE of 75% and 14.3%, 
respectively (p = 0.0133). The 36 months cumulative survival rate in patients treated 
with LA and TACE was 55.4% and 48.8%, respectively. The disease recurrence rates 
after LA and TACE were 19.5% and 75.0%, respectively.
Conclusions: LA is a more effective therapeutic option than TACE in patients with 
solitary large HCC.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
frequent cancer among males and the ninth in women 
worldwide. In 2012, 782000 new HCC cases were 
registered [1]. The clinical and radiological presentations 
of HCC are extremely variable and a single HCC lesion 
with a diameter >40 mm is diagnosed in about 27% of 
cases (ITA.LI.CA unpublished data). In these patients the 
first line treatment is liver resection [2, 3]. Among patients 
unsuitable for surgery the treatment of solitary large HCC 
(>40 mm) is highly debated and its management represents 
a difficult challenge for clinicians. The standard treatment 
for these patients is transarterial chemoembolization 
(TACE) despite its unsatisfactory efficacy (complete 
response only in 25% of subjects [4]), with the occurrence 
of serious side effects in >10% of cases [5], and with an 
estimated 1-year recurrence rate of 59% [6]. Over the 
                                                   Research Paper
Oncotarget17484www.oncotarget.com
last two decades, local thermal ablative techniques have 
gained popularity and are considered the best treatment 
for unresectable early HCC with a size up to 30 mm [7, 8]. 
Percutaneous ablation has been attempted also in tumours 
larger than 30 mm, but these data are currently scarce. The 
most widely used techniques for treating large HCC are 
radiofrequency (RFA) and microwave (MWA) ablation 
with success rates of 83.4% and 86.7%, respectively [9]. 
Laser ablation (LA) is a less known and implemented in 
routine practice, despite the evidence of its non-inferiority 
compared to RFA in the treatment of early HCC [10]. 
Moreover, in a preliminary case-series study, LA with the 
multifiber technique achieved a complete response in 71% 
of nodules > 40 mm with mild side effects [11]. The aim 
of this case-control study was to evaluate the efficacy of 
LA in comparison to TACE in patients with unresectable 
solitary large HCC (≥ 40 mm). Our study was focused 
on this specific patients subgroup (solitary large HCC ≥ 
40 mm) because traditional thermal ablation techniques 
(RFA and MWA) are considered less effective than TACE 
in obtaining a complete response [8–10].
RESULTS
Baseline characteristics of the two groups of patients 
and HCC nodules are summarized in Table 1. No clinical 
and tumour findings were significantly different between 
the two groups, except for aetiology of underlying 
cirrhosis; HCV infection was more frequent in LA than in 
the TACE group (78% vs 53.7%; p = 0.036), while in the 
last group the alcoholic aetiology was more represented 
(19.5% vs 2.4%; p = 0.034). 
Efficacy
LA approach resulted more effective than TACE 
in inducing a complete tumour ablation. Overall, 26 
(63.4%) patients from the LA group and 8 (19.5%) from 
the TACE group showed a complete response to treatment 
(p < 0.001). At univariate analysis, baseline predictors of 
complete response were Child-Pugh class A and treatment 
modality with LA (Table 2). 
Furthermore, HCC were stratified into 3 categories 
according to the nodule size: 40-50 mm, 51-60 mm, and 
>60 mm. The complete response rate according to nodule 
size is reported in Figure 1. LA resulted more effectively 
than TACE in all the categories, especially in nodules 
with the diameter ranging between 51 and 60 mm, with 
complete response rates after LA and TACE of 75% and 
14.3%, respectively (p =  0.013). 
Disease recurrence rate
During a mean ± SD follow-up period of 37.4  ± 
20.7 months (LA 37.8 ± 20.9–TACE 37.0 ± 20.7) the 
disease recurrence was observed in 5/26 LA-successfully 
treated patients (19.5%) and in 6/8 TACE-successfully 
treated patients (75.0%) (p < 0.0001). The mean times 
to recurrence was 42.2 months (95% CI, 34.3-50.1) and 
26.8 months (95% CI, 18.6-34.9) in LA and TACE group, 
respectively (p = 0.004). Mean disease-free survival 
period were 31.5 months (95%CI, 24.1-38.8) among LA 
group patients and 14.2 months (95% CI, 9.7–18.7) among 
TACE group patients (p < 0.0001; HR 0.64). 
At univariate analysis, time to recurrence was only 
influenced by treatment modality (LA vs TACE) and 
MELD value (Table 3). 
Survival analysis
The mean OS was 38.3 months (95% CI, 33.8-42.9). 
Among the LA patients, it was 39.7 months (95% CI, 33.1-
46.4) while 37.0 months (95% CI, 30.7-43.3) for TACE 
group (p = 0.725) (Figure 2). Overall survival probability 
rates at 1-year, 2-years, and 3-years were 90.2%, 65.5%, 
and 55.4% in LA group and 85.4%, 65.9%, and 48.8% in 
TACE group (Figure 2). 
During the study period 50 patients died; 24 patients 
in LA group and 26 in TACE group. The cause of death 
was unknown in 6 patients of LA group and in 1 patient of 
TACE group. HCC progression was observed in 53% (12 
patients) and 64% (16 patients) and liver failure in 29% 
(6 patients) and 36% (9 patients) of LA and TACE group, 
respectively.
DISCUSSION
Over the past 20 years laser ablation technique 
has been developed and improved for the treatment of 
HCC [10]. Cohort series, retrospective studies and a non-
inferiority randomized controlled trials demonstrated 
that this technique is effective in treating HCC and is 
non-inferior to the widely used RFA [12–15] in nodules 
<30 mm. On the other hand, information for nodules >40 
mm derives from a single preliminary report using the 
multifiber technique achieving a complete response in 
71% of nodules [11]. 
Currently, the standard treatment for patients 
with solitary large HCC (≥40 mm) is TACE, despite its 
suboptimal rate of complete ablation (about 25%) in 
relation to the nodule size [4] and with serious side effects 
in > 10% of cases [5].
Alternative therapeutic procedures have been 
proposed such as transarterial radioembolization (TARE), 
a selective intra-arterial liver injection using yttrium-90-
loaded microspheres. This type of treatment is considered 
a good choice in large tumours (up to 10 cm) especially 
with multiple satellite nodules [16]. The complete response 
rate after TARE is 40-50%, although the rate of efficacy 
derives almost exclusively by a large and heterogeneous 
cohort of subjects with both solitary or multifocal large 
HCC [16]. 
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Monopolar RFA is the most widely used technique 
to perform local ablation. Its efficacy is reduced when it 
is used for treating nodules larger than 30 mm. In these 
cases, multiple overlapping ablations or switching the RFA 
mode using three separate needles have been used [17, 18]. 
Multipolar RFA with three electrodes is less investigated, 
but seems promising to increase the volume of the 
ablated area [19]. In recent years, MWA is emerging as an 
alternative to RFA for thermal destruction of HCC because 
it induces higher intratumoral temperature in a very short 
time. In two recent meta-analyses, this technique seems to 
reduce the local recurrence rate in large nodules (≥50 mm) 
as compared to RFA [20, 21].
A clear state-of-the-art treatment of large HCC 
remains an unmet clinical need and more effective 
therapies are required.
To better explore the efficacy of LA for treatment of 
large solitary unresectable HCC, we conducted this case-
control study comparing LA with TACE, that is considered 
the current standard of care [22].
Our study indicates that multifiber LA approach is 
more effective than TACE in treating solitary large (≥40 
mm) unresectable HCC, by obtaining a complete tumour 
ablation (achieved in about 2/3 of patients, 63.4%) and by 
reducing the recurrence rate (19.5% vs 75.0%, both with a 
statistically significant difference). 
Table 1: Baseline characteristics of the HCC population according to treatment options (LA vs TACE)
LA group TACE group p value
n % n %
Male/Female 29/12 (70.7/29.3) 29/12 (70.7/29.3) 1
Age, years, median (range) 72 (54–88) 72 (49–86) 0.603
BMI, median (range) 27.3 (17.2–36.6) 26.1 (17.7–32.0) 0.136
Liver disease etiology
 HCV infection 32 78.0 22 53.7 0.036
 HBV infection 2 4.9 3 7.3 1
 Alcohol 1 2.4 8 19.5 0.034
 Others 6 14.7 8 19.5 1
Comorbidities
 none 13 31.7 16 39.0
0.508
 metabolic  4 9.8  7 17.1
 cardiovascular 14 34.1 13 31.7
 metabolic + cardiovascular  9 22.0  5 12.2
 pulmonary  1 2.4  0 0.0
Child-Pugh class
 A 34 82.9 37 90.2
0.519
 B  7 17.1  4 9.8
BCLC stage
 A 27 65.9 28 68.3
0.275
 B 14 34.1 13 31.7
Tumour size, mm, median 
(range)
46 (40–75) 47 (40–76) 0.16
Nodule size >50 mm 13 (31.7%) 14 (34.1%) 0.492
Table 2: Univariate analysis of variables potentially related to complete tumour response
Variables Complete response n = 34 Non responders n = 48 p value
Male gender 23 (67,6%) 35 (72.9%) 0.630
Age > 70 19 (55.9%) 30 (62.5%) 0.649
Child-Pugh A 33 (97.1%) 38 (79.2%) 0.022
LA 26 (76.5%) 15 (31.3%) <0.001
Nodule size <5 cm 24 (70.6%) 28 (58.3%) 0.352
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Overall LA was superior to TACE in all the nodule-
size categories, but especially in nodules with diameters 
ranging between 51 and 60 mm, with a complete response 
rate of 75% in comparison to complete response of 14.3% 
observed after TACE procedure. Differently to TACE, 
LA shows efficacy in relation to nodule size [4]. Its 
effectiveness seems to be regardless of the nodule size, at 
least for nodules sizing less than 60 mm. For nodules with 
diameter >60 mm a reduction of the complete response 
rate was observed, although the LA remains more 
efficacious than TACE. In addition to a more efficient 
ablation, LA is able to reduce the rate of recurrence. 
The local recurrence rate after TACE widely varies 
from 30 to 70 % across published studies [4, 23, 24].
In our experience in patients treated with LA the 
recurrence rate was 19.5% compared to 75.0% of TACE-
treated patients. Thus, LA is able to halve the disease 
recurrence rate during a follow-up period of 37 months. 
The principal reason for the better outcome is probably 
due to a higher effectiveness in term of local tumour 
control with larger ablative margins and the elimination of 
peripheral satellite nodules or occult foci of cancer cells 
[25, 26]. 
The survival rates of our patients at 1-year, 2-years, 
and 3-years were 90.2%, 65.5%, and 55.4% in LA group 
and 85.4%, 65.4%, and 48.8% in TACE group, without 
any statistically significant differences between the two 
procedures. Although there is no clear explanation for the 
discrepancy between primary effectiveness rate (complete 
lesion ablation) and the long term outcome (survival), 
the literature suggests that the two outcomes do not 
necessarily overlap [27]. On the other hand, a large series 
of studies reports that survival depends not only by the 
efficacy of treatment but also by several factors like age, 
comorbidities, stage of chronic liver disease, nodule size, 
and efficacy of subsequent treatment of HCC in patients 
with residual lesions. Our series of patients are well-
matched for these factors, although some small differences 
not statistically significant, could potentially explain the 
survival rates in the 2 groups of patients. 
Additionally, very poor information is available 
in the literature regarding long-term survival rates after 
treatment of patients with solitary large HCC. In a series 
of 64 patients with large lesion treated with MWA vs 
< TACE, the survival rates after 12 and 18 months of 
follow-up were 78.2% and 68.4% in the MWA group and 
52.4% and 28.8% in the TACE group, respectively [28]. 
Contrarily, our study is the first reporting the efficacy of 
LA in solitary large nodules with a long-term follow-up 
period (3 years).
Our study has some limitations that we now briefly 
discuss. Firstly, our work uses an historical control 
group and therefore it may suffer from unintended 
biases specifically related to the retrospective design 
of the database. Secondly, the small sample size of 
the two analyzed groups could be a limiting factor as 
statistical tests normally require a larger sample size to 
ensure a representative distribution of the population 
and generalized extrapolation. Nonetheless, it should be 
underlined that this particular HCC “stage” specifically 
treated with this approach is not common. Finally, 
the comparison between a single center cohort with a 
multicenter cohort could represent another bias as per 
definition single center cohorts concentrate expertise 
while multicenter cohorts include different kind of centers, 
despite the fact that the ITALICA group is composed by 
Italian expert centers in HCC treatment.
The indisputable advantage of this study is that it 
benefit from a single-center group of LA patients with a 
the long-term operator experienced in performing LA. To 
the best of our knowledge, this study represents the first 
and largest cohort with single large HCCs, exclusively 
investigated for treatment with LA with a long term 
outcome. This is of particular relevance given the limited 
Figure 1: Complete response rates according to nodule size and treatment options (LA vs TACE).
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therapies available for large unresectable HCC with a 
curative intent.  
In conclusion, the results of this study suggest that 
LA may be a valuable alternative to TACE in the treatment 
of patients with large HCC in which surgical resection is 
unsuitable or inappropriate. LA was superior to TACE 
especially in nodules with a diameter ranging between 40 
and 60 mm. Nevertheless, larger well-designed randomized 
controlled trials are needed to confirm our results. 
MATERIALS AND METHODS
Patients
This is a retrospective case-control study approved 
by the local institutional review board. Inclusion criteria 
were: i) unresectable HCC (due to nodule location, 
presence of portal hypertension, age >75 years, or 
comorbidities) or refusal of surgery; (ii) solitary HCC ≥40 
mm; (iii) BCLC stage A or B; (iv) Child–Pugh class A 
or B cirrhosis; (v) platelet count > 40 000/μL and INR 
<2.0; and (vi) no history of previous HCC treatment. 
Exclusion criteria included: (i) history of encephalopathy 
or refractory ascites; (ii) vascular invasion or extrahepatic 
metastasis; (iii) severe comorbidities reducing life 
expectancy; (iv) BCLC stage C or D; (v) Child–Pugh class 
C cirrhosis.
Between January 2009 and December 2012, a total 
of 432 naïve HCC cirrhotic patients were consecutively 
observed at the Liver Unit of Cardarelli Hospital, Naples, 
Italy. Among them, 41 consecutive cirrhotic patients with 
a single HCC nodule ≥ 4.0 mm in diameter met the entry 
Table 3: Univariate analysis of variables potentially related to HCC time to recurrence
 Mean TTR (months) 95%CI p
LA 42.19  ±  4.01 34.326–50.069
0.004
TACE 26.77  ±  4.17 18.590–34.951
Child-Pugh A 33.664  ±  3.270 27.254–40.073
0.592
                    B 39.400  ±  7.995 23.729–55.071
BCLC A 30.938  ±  3.270 22.900–38.977
0.405
           B 38.137  ±  4.504 29.309–46.964
MELD >10 24.748  ±  4.946 15.053–34.443
0.018
             ≤ 10 39.357  ±  3.716 32.074–46.640
TTR: Time to recurrence.
Figure 2: Overall survival according to treatment options: LA (continuous line) and TACE (dotted line).
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criteria and were enrolled into the study. All 41 patients 
were treated with LA treatment. 
The control group was obtained from the Italian 
Liver Cancer (ITA.LI.CA.) database [29] and was 
represented by 41 patients who met the same inclusion and 
exclusion criteria undergoing a TACE treatment within the 
same time-frame.  
The diagnosis of HCC was based on the European 
Association for the study of the Liver (EASL) guidelines 
for HCC management [22]. The patients were classified 
according to Barcelona Clinic Liver Cancer (BCLC) 
Staging System [30]. The size and number of the HCC 
lesions and their location in the liver were established by 
ultrasound and contrast enhanced Computed Tomography 
(CT) or Magnetic Resonance Imaging (MRI). In particular, 
for both diagnostic work-up and follow-up, CT scan and 
MRI were considered equally given the large size of the 
nodules [31]. Portal hypertension was defined according 
to the EASL guidelines. 
Treatment procedures
The term laser ablation refers to the thermal 
destruction of tissue by conversion of absorbed light 
(usually infrared) into heat. Infrared energy penetrates 
tissue directly for a distance of 12–15 mm, although 
heat is conducted beyond this range creating a larger 
ablative zone [31]. Optical penetration has been shown 
to be increased in malignant tissue compared to normal 
parenchyma. The details of LA procedure have been 
reported elsewhere [27, 32, 33]. 
In the present study LA was performed with the 
multifiber technique. In cases of nodules up to 50 mm four 
fibers arranged in a square configuration were employed; 
for larger nodules eight fibers positioned in a two-square 
configuration were used. Twenty-five and 7 patients 
received respectively two and three LA treatment sessions. 
Patients with residual cancer subsequently received 
combined treatments (thermal ablation plus TACE) and in 
case of no response to this combined modality sorafenib 
was used.
Conventional TACE was performed by injection of 
epirubicin, lipiodol and an embolizing agent after selective 
catheterization of the hepatic arteries feeding the lesion, 
according to the standardized protocol (all of the enrolled 
patients received at least 2 TACE treatment sessions) [34].
Outcomes and assessments
The main outcome was the complete response rate 
to treatment. Response to therapy was evaluated with 
contrast enhanced CT or MRI twelve weeks after the last 
TACE or LA session according to the modified Response 
Evaluation Criteria in Solid Tumours (mRECIST) 
[33]. Complete response after LA was defined as the 
disappearance of any intratumoral arterial enhancement 
in target lesions. The response after TACE was defined 
complete when a homogeneous uptake of lipiodol and 
a complete absence of intratumoral enhancement was 
observed in the target lesions at CT scan or when MRI 
showed absence of any enhancement within the nodules. 
Secondary outcomes were the evaluation of local 
tumour progression (LTP) and overall survival (OS). All 
patients underwent follow-up investigations, including 
α-fetoprotein measurement and ultrasonography 
assessment every 3 months, CT or MRI every 6 months, 
and in any suspected case of tumoural recurrence. LTP was 
defined as reappearance of arterial enhancement on CT or 
MRI either within a treated tumour or near its margins. 
OS was calculated from the time of cancer diagnosis to 
death with values censored at the date of the last follow-
up. For the TACE group, details on the ITA.LI.CA data 
base management have been already reported [35].
Statistical analysis 
Categorical variables were summarized as numbers 
and percentages; continuous variables were presented 
as median, range, standard deviation (SD) and 95% 
confidence intervals (95% CI). Categorical data were 
compared using a Chi-square test and continuous variables 
by Mann-Whitney test. The two-sided probability value 
<0.05 was considered statistically significant. Kaplan-
Meier method was used to estimate overall survival. 
Survival was calculated from the date of diagnosis to 
the date of death. Patients who were alive at the time of 
the analysis were censored at the last follow-up time. 
Differences in survival times between groups were 
assessed by the log-rank test.
Univariate analysis to search for factors associated 
to complete ablation, recurrence-free survival and OS was 
performed evaluating Child-Pugh class (A vs B), MELD 
score (<10 vs ≥10), BCLC class (A vs B), and treatment 
(LA vs TACE). All of the analyses were performed with 
software package SPSS for Mac (Rel SPSS 21.0; IBM 
corporation, 2012).
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